RxDoctor Payments DataLook up a doctor →

Stephen Dickson, MD

Cardiovascular Disease · Independence, MONPI 1023422474

Payments from drug & device makers

$97,810in general payments, 2019–2025

Across 482 payments — averaging $202.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$74K
  • Lilly USA, LLC$12K
  • Novo Nordisk$5K
  • Boston Scientific$1K
  • Novartis$977
  • Amgen$815
  • plus $3K from 33 others

What the payments were for

  • Consulting fees$4,6505%
  • Speaking & faculty fees$81,90084%
  • Travel & lodging$2,4503%
  • Food & beverage$8,7779%
  • Education$320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$97,810 in reported general payments places this provider in the 90th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$147,433
Medicare patients
828
Services billed
2,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan413$474,015
JardianceEmpagliflozin375$417,337
EliquisApixaban282$304,316
XareltoRivaroxaban132$127,540
OzempicSemaglutide53$64,602
Repatha SureclickEvolocumab52$45,203
FarxigaDapagliflozin Propanediol37$29,077
Repatha SyringeEvolocumab12$13,259
Metoprolol Succinate480$6,536
Atorvastatin Calcium377$4,612
Rosuvastatin Calcium375$3,917
Ezetimibe180$3,496
Spironolactone495$3,317
Carvedilol395$3,164
Losartan Potassium290$2,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$977$474,015413 claims
Boehringer IngelheimJardiance$74,118$417,337375 claims
PfizerEliquis$323$304,316282 claims
Johnson & JohnsonXarelto$355$127,540132 claims
Novo NordiskOzempic$5,042$64,60253 claims
AstraZenecaFarxiga$184$29,07737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Independence

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →